Here we showed, in a cohort of 78 MS-RR individuals undergoing immune-modulating treatment, a correlation between the intracellular content of SOD-1 in T cells and the increasing presence of circulating Treg expressing the exon 2 of Foxp3 molecule, largely associated with effective Treg immunomodulatory properties [21,22]. Here, SOD1 is linked to myeloid sarcoma.